Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH), the hypothalamic peptide that stimulates growth hormone release from the pituitary. A trans-3-hexenoyl group on the N-terminal tyrosine makes it resistant to cleavage by dipeptidyl peptidase-IV (DPP-IV), and its average molecular weight is about 5,136 Da. In the laboratory it is studied as a stabilised agonist of the GHRH receptor, a Gs-coupled class B G protein-coupled receptor (GPCR), and as a model for peptide stabilisation by N-terminal acylation. This article covers its structure, mechanism, published research, applications and handling requirements.
What is tesamorelin?
Tesamorelin is the full-length human GHRH(1-44) amide with a single chemical modification. The peptide has 44 residues and an amidated C-terminus, and a trans-3-hexenoyl group is attached to the α-amine of the N-terminal tyrosine. The sequence is (trans-3-hexenoyl)-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2. The molecular formula is C221H366N72O67S, and the average molecular weight is about 5,135.9 Da. It is also referred to as TH9507, its development code, and the acetate salt is the form commonly supplied.
The compound was developed in Canada by Theratechnologies as TH9507. The design principle was minimal change: retain the entire native sequence, so that receptor recognition is preserved, and cap the N-terminus with a small lipophilic acyl group so that the enzyme that normally inactivates GHRH can no longer cleave it. A non-clinical pharmacology study published in 2007 described TH9507 as an analogue of hGRF(1-44)NH2 minimally modified by adding a trans-3-hexenoyl moiety to Tyr1, and reported that it was resistant to DPP-IV inactivation.
The background to the discovery of GHRH itself is well documented. Groups led by Roger Guillemin and by Jean Rivier and Wylie Vale isolated and sequenced a growth hormone-releasing factor from a human pancreatic tumour in 1982, and Ling and colleagues later isolated the hypothalamic form. Native GHRH has 44 residues, and the first 29 are sufficient for full receptor activity, which is why the shorter fragment sermorelin and other 1-29 analogues exist. Tesamorelin differs from those because it keeps the complete 44-residue chain. Related names include “tesamorelin acetate” and “GHRH(1-44) analogue”, and these refer to the same family of material.
Two practical consequences follow from the size of the molecule. Peptides of 44 residues are difficult to synthesise, so deletion and truncated sequences are more common than in short peptides. The methionine at position 27 and the asparagine and glutamine residues are potential sites of oxidation and deamidation. Both points affect how the material should be verified.
Mechanism of action
Tesamorelin acts on the GHRH receptor (GHRHR), a class B GPCR expressed on pituitary somatotrophs. Like other class B receptors, GHRHR has a large N-terminal extracellular domain and a seven-transmembrane core. In 2020, Zhou and colleagues reported a 2.6 Å cryo-EM structure of human GHRHR bound to GHRH and the stimulatory G protein Gs. The structure shows that the α-helical GHRH engages the receptor through an extensive network of interactions that involves all the extracellular loops, nearly all transmembrane helices and the extracellular domain, and that the N-terminus of the peptide inserts into the transmembrane core to drive activation.
Receptor activation couples to Gs, which stimulates adenylyl cyclase and raises intracellular cyclic AMP. This activates protein kinase A and the transcription factor CREB, which, together with the pituitary-specific factor Pit-1, promotes transcription of the growth hormone gene and the release of stored hormone. The released growth hormone then acts on tissues such as the liver, where it induces insulin-like growth factor 1 (IGF-1), so growth hormone and IGF-1 concentrations are standard downstream readouts in animal studies.
The hexenoyl group changes the pharmacokinetics, not the pharmacology. Native GHRH is cleaved by DPP-IV at the Tyr1-Ala2 bond, which generates an inactive GHRH(3-44) metabolite. The acyl cap hinders this cleavage while leaving the receptor-binding determinants, which lie mainly in the N-terminal region and the helical body of the peptide, intact. The non-clinical study described below reported that the modification slowed degradation in rat, dog and human plasma compared with the native peptide. In cell-based work, tesamorelin therefore behaves as a longer-lasting GHRHR agonist, and potency figures from assays that contain serum or tissue should not be compared with those for the unmodified peptide without that context.
What the research shows
Four sets of published work frame the field.
The first is the non-clinical characterisation of the compound. Published in Basic & Clinical Pharmacology & Toxicology in 2007, this study of TH9507 reported that the hexenoyl modification made the peptide resistant to DPP-IV and slowed its degradation in rat, dog and human plasma. Plasma growth hormone and IGF-1 rose markedly in pigs, rats and dogs after daily repeat intravenous or subcutaneous injections at doses up to 600 μg/kg, and sub-chronic studies of up to four months in rats and dogs found a significant, but not dose-related, increase in body weight gain. The authors also reported reversible adverse findings in dogs, including liver and kidney changes and anaemia, which they attributed to prolonged exposure to supraphysiological levels of growth hormone and IGF-1, and an apparent elimination half-life of 21 to 45 minutes in dogs. The paper is indexed on PubMed.
The second is the structural study of the receptor. Zhou and colleagues, in Nature Communications in 2020, determined the cryo-EM structure of human GHRHR in complex with GHRH and Gs, used mutagenesis and molecular dynamics simulations to explain how receptor mutations impair signalling, and described the recognition pattern of the helical ligand. The study used the native peptide, so the tesamorelin-bound state is inferred, but it provides the best current model for how the whole GHRH(1-44) sequence engages the receptor. It is available on PubMed.
The third is the discovery work noted above. The isolation of GHRH from tumour and hypothalamic tissue in the early 1980s, and the structure-activity studies that showed the 1-29 fragment to be fully active, established the sequence from which tesamorelin is derived.
The fourth is a research area, not a single paper: the enzymology of GHRH inactivation. Early work on native GRF showed rapid degradation by DPP-IV in plasma, and later studies tested N-terminal substitutions and acylation as strategies to protect analogues. Readers should consult the primary literature for the specific substitutions and assay conditions, which vary between papers.
Research applications
Receptor pharmacology is the main use. Cell lines expressing human GHRHR, and primary pituitary cell cultures, are stimulated with tesamorelin and its comparators, and responses are measured by cyclic AMP accumulation, CRE-reporter activity or growth hormone release into the medium. The compound is used as a stabilised reference agonist, and compared with native GHRH(1-44), sermorelin and other GRF analogues in order to rank potency and duration of action.
Peptide stability research is a second area. The pair of native GHRH(1-44) and tesamorelin is a clean model for studying how a single N-terminal acyl group protects a peptide from DPP-IV in plasma or serum-containing media, and such assays often include DPP-IV inhibitors as controls. Animal research is a third, in which licensed investigators use the compound to study the somatotropic axis in rodents, pigs and dogs under the Animals (Scientific Procedures) Act 1986, with growth hormone and IGF-1 as readouts.
Analytical chemistry is a fourth. A 44-residue acylated peptide is a useful test substance for HPLC and mass spectrometry method development, particularly for resolving oxidised, deamidated and acyl-isomer impurities. Structural and biophysical research is a fifth, including studies of the peptide’s helical content by circular dichroism and of its aggregation behaviour in solution.
Purity, storage and handling
Verification starts with reversed-phase HPLC, monitored at 214 nm and at about 280 nm for the two tyrosine residues. For a peptide of this length, purity of 95% or above is a realistic specification, and the gradient should be long enough to resolve closely related species. Mass spectrometry should confirm the intact mass of about 5,135.9 Da. In electrospray spectra, the peptide appears as a series of multiply charged ions, so the spectrum must be deconvoluted. Likely impurities include deletion and truncated sequences, oxidised methionine (+16 Da), deamidated forms (+1 Da) that must be resolved chromatographically, the des-acyl peptide, and positional isomers of the unsaturated acyl group. Net peptide content is a separate figure, since the powder contains acetate counter-ions and water.
Because degradation accelerates once reconstituted, batch-level HPLC verification matters more here than with more stable peptides. UK laboratories sourcing Tesamorelin should expect a batch-specific certificate of analysis and lyophilised storage at -20°C, and researchers asking How to buy best peptides can use those documentation requirements as a first filter when comparing vendors.
A batch-specific certificate matters because the impurity profile of a 44-residue peptide depends strongly on the efficiency of every coupling step and on the cleavage conditions, and because the acyl modification adds a second chemical step that must be confirmed. The certificate should give the batch number, HPLC conditions and chromatogram, the observed deconvoluted mass, confirmation of the N-terminal modification, the counter-ion and its content, the net peptide content and the test date. Endotoxin testing is advisable for cell-based work.
Lyophilised peptide is generally stored at -20°C, sealed and desiccated, and brought to room temperature before opening so that moisture does not condense on the powder. Reconstituted peptide is much less stable. Methionine can oxidise, the asparagine and glutamine residues can deamidate, and long helical peptides can adsorb to plastic and aggregate, particularly at higher concentration or after agitation. Solutions should therefore be mixed by gentle swirling and not by vortexing, kept at 2-8°C for short periods, and divided into single-use aliquots to avoid repeated freeze-thaw cycles, with low-binding tubes preferred. Exact stability windows depend on diluent, pH and concentration, so they should be taken from supplier data and confirmed in-house for critical assays.
Light sensitivity is moderate. The two tyrosine residues can undergo photo-oxidation, so amber vials or dark storage are advisable. Standard COSHH assessment and institutional waste procedures apply.
Frequently asked questions
What is tesamorelin and how does it differ from sermorelin?
Tesamorelin is a 44-residue GHRH analogue with a trans-3-hexenoyl group on the N-terminal tyrosine, while sermorelin is the shorter GHRH(1-29) fragment without that group. Both act on the GHRH receptor, but the N-terminal cap makes tesamorelin more resistant to DPP-IV, and its larger size makes it harder to synthesise and analyse.
What is the molecular weight and sequence of tesamorelin?
Tesamorelin has 44 amino acids, a C-terminal amide and a trans-3-hexenoyl group on Tyr1. Its formula is C221H366N72O67S and its average molecular weight is about 5,135.9 Da. Mass spectrometry shows multiply charged ions, so the spectrum must be deconvoluted to confirm the intact mass.
Why is tesamorelin resistant to DPP-IV?
DPP-IV cleaves native GHRH at the N-terminal Tyr1-Ala2 bond, which inactivates it. Tesamorelin carries a trans-3-hexenoyl group on Tyr1 that hinders this cleavage, and published non-clinical work reported slower degradation in rat, dog and human plasma than for the native hGRF(1-44) peptide.
How should lyophilised tesamorelin be stored?
Lyophilised tesamorelin is generally stored at -20°C in a sealed, desiccated container protected from light, and warmed to room temperature before opening. Reconstituted solutions should be mixed gently, kept at 2-8°C for short periods as single-use aliquots, and checked against batch stability data.
Tesamorelin is supplied for in-vitro laboratory research only. It is not for human or veterinary use, and it must not be administered to people or animals.